Edition:
United States

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

16.80USD
16 Jan 2019
Change (% chg)

-- (--)
Prev Close
$16.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
308,107
52-wk High
$36.25
52-wk Low
$12.86

Chart for

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $944.98
Shares Outstanding(Mil.): 47.56
Dividend: --
Yield (%): --

Financials

  ACOR.OQ Industry Sector
P/E (TTM): -- 95.96 30.88
EPS (TTM): -2.91 -- --
ROI: -11.10 0.60 13.80
ROE: -20.93 -2.18 15.29

U.S. appeals court invalidates Acorda patents on MS drug

A U.S. appeals court on Monday invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door to generic competition for the company's flagship product.

Sep 10 2018

UPDATE 1-U.S. appeals court invalidates Acorda patents on MS drug

Sept 10 A U.S. appeals court on Monday invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door to generic competition for the company's flagship product.

Sep 10 2018

UPDATE 2-Acorda loses bid for U.S. court order halting generic Ampyra sales

July 25 A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

Jul 25 2018

Acorda loses bid for U.S. court order halting generic Ampyra sales

A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

Jul 25 2018

Earnings vs. Estimates